Clinique Victor Hugo
Le Mans, 72015, France
NCT Number: NCT00536393
Interest of the use of pegylated liposomal doxorubicin (caélyx)
Looking for future studies?
Notify Me60 year–75 year
All sexes
Interventional
Phase 2 / Phase 3
Le Mans, 72015, France
R CHOP is a good standard in the treatment of diffuse high grade lymphoma. Howeverin elderly patients it is often toxic, specially with haematologic and cardiac toxicities.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
French Innovative Leukemia Organisation
Other
Phase III Study of Treatment of Disseminated and Agressive Lymphoma R CHOP Versus R CLOP( With Liposomal Doxorubicin)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial DetailsNCT01563874
Hemic and Lymphatic Diseases, Immune System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04837222
Hemic and Lymphatic Diseases, Immune System Diseases
Hefei, Anhui, China
View Trial DetailsNCT04737265
Breast Cancer, Breast Diseases
Duarte, California, United States
View Trial Details